Long-term follow-up confirms that radiotherapy followed by 12 cycles of adjuvant temozolomide without concurrent temozolomide during radiotherapy improves survival for individuals with aggressive IDHmt astrocytoma.
[Articles] Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial
The Lancet Oncology | | Martin J van den Bent, Santoesha A Ghisai, Wolfgang Wick, Marc Sanson, Alba Ariela Brandes, Paul M Clement, Sara C Erridge, Michael A Vogelbaum, Anna K Nowak, Jean-François Baurain, Warren P Mason, Helen Wheeler, Emeline Tabouret, Sanjeev Gill, Matthew Griffin, Walter Taal, Roberta Rudà, Michael Weller, Catherine McBain, Jaap C Reijneveld, Roelien H Enting, Sébastien Tran, Thierry Lesimple, Martin Kocher, Anja Gijtenbeek, Elizabeth Lim, Ulrich Herrlinger, Peter Hau, Frederic Dhermain, Kenneth Aldape, Robert B Jenkins, Hendrikus Jan Dubbink, Johan M Kros, Pieter Wesseling, Youri Hoogstrate, Sarah Nuyens, Vassilis Golfinopoulos, C Mircea S Tesileanu, Thierry Gorlia, Pim French, Brigitta G Baumert
Topics: brain-cancer, radiation, clinical-trials, research